london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Ocriplasmin - the first 3 cases injected in Portugal

Poster Details

First Author: C.Teixeira PORTUGAL

Co Author(s):    Â. Carneiro   J. Nascimento               0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To evaluate the results of the first three Portuguese cases of symptomatic vitreomacular traction (VMT) treated with intravitreal ocriplasmin.

Setting:

Multicenter

Methods:

Prospective cases series. Patients were selected to receive a single intravitreal injection of 0.125 mg ocriplasmin (Jetrea, Alcon/Novartis), with the reconstitution technique recommend by the manufacturer, according to predictor criteria such as age, no epirretinal membrane at baseline, VMT diameter ≤ 1500 microns, macular hole ≤ 400 microns and phakic lens status. Primary outcome was the resolution of VMT at day 28 by optical coherence tomography (OCT) and the secondary outcomes were time to vitreous traction release, visual acuity (at day 28, 60, 90) and OCT foveal changes.

Results:

Case series included the first three Portuguese patients and resolution of VMT was verified in two patients by day 28 (66.7%). VMT resolved by day 3 in one patient and by day 14 in another. Best corrected visual acuity (BCVA) improved or remained stable in all the patients with resolution of VMT. Patients meeting all five predictor criteria showed a response rate of 100%. Some initial changes were found on OCT of patients successfully treated such as hiperreflectivity of retina below the inner limiting membrane or irregularity of retinal pigment epithelium (RPE) and basement membrane. The case failed to resolve VMT was a 75 years old patient with all the other four criteria and a macular hole ≤ 400 microns, BCVA at baseline was 20/200 and remained the same by day 28. No ocular adverse events were registered.

Conclusions:

Ocriplasmin is a secure and useful treatment for patients with symptomatic VMT.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy